Current experience with itraconazole in neutropenic patients: A concise overview of pharmacological properties and use in prophylactic and empirical antifungal therapy

Clinical Microbiology and Infection

Volumn 12, Issue SUPPL. 7, 2006, Pages 84-90

  Glasmacher, A ^a   Prentice, A ^b  

^a UNIVERSITY OF BONN   (Germany)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antifungal prophylaxis; Empirical antimycotic; Invasive fungal infections; Itraconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ASTEMIZOLE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CASPOFUNGIN; CISAPRIDE; CYCLODEXTRIN; CYCLOSPORIN; DIGOXIN; FLUCONAZOLE; ISONIAZID; ITRACONAZOLE; MIDAZOLAM; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TERFENADINE; TRIAZOLAM; TRIAZOLE DERIVATIVE; TSUKUBAENOLIDE; VORICONAZOLE;

ANTIBIOTIC THERAPY; ASPERGILLOSIS; ASPERGILLUS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG SOLUTION; DRUG USE; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH RISK PATIENT; HUMAN; INFECTION PREVENTION; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; REVIEW;

ASPERGILLUS;

EID: 33751050958     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2006.01609.x     Document Type: Review

References (54)

1. Cauwenbergh G, de Doncker P, Stoops K, De Dier AM, Goyvaerts H, Schuermans V. Itraconazole in the treatment of human mycoses: Review of three years of clinical experience. Rev Infect Dis 1987; 9 (suppl 1): S146-S152.
2. Van Cutsem J, Van Gerven F, Janssen PA. Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: Animal models. Rev Infect Dis 1987; 9 (suppl 1): S15-S32.
3. Grant SM, Clissod SP. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-344.
4. Persat F, Marzullo C, Guyotat D, Rochet MJ, Piens MA. Plasma itraconazole concentrations in neutropenic patients after repeated high-dose treatment. Eur J Cancer 1992; 28A: 838-841.
5. Heykants J, van Peer A, van de Velde V et al. The clinical pharmacokinetics of itraconazole: An overview. Mycoses 1989; 32 (suppl 1): 67-87.
6. Glasmacher A, Molitor E, Mezger J, Marklein G. Antifungal prophylaxis with itraconazole in neutropenic patients: Pharmacological, microbiological and clinical aspects. Mycoses 1996; 39: 249-258.
7. Glasmacher A, Hahn C, Molitor E, Sauerbruch T, Schmidt-Wolf IGH. Itraconazole trough levels in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999; 42: 591-600.
8. Hostetler JS, Hanson LH, Stevens DA. Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother 1992; 36: 477-480.
9. Barone JA, Moskovitz BL, Guarnieri J et al. Enhanced bioavailability of itraconazole in hydroxypropyl-β-cyclodextrin solution versus capsules in healty volunteers. Antimicrob Agents Chemother 1998; 42: 1862-1865.
10. Willems L, Van Der GR, de Beule K. Itraconazole oral solution and intravenous formulations: A review of pharmacokinetics and pharmacodynamics. J Clin Pharm Ther 2001; 26: 159-169.
11. Prentice AG, Warnock DW, Johnson SA, Taylor PC, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia. J Antimicrob Chemother 1995; 36: 657-663.
12. Prentice AG, Warnock DW, Johnson SA, Phillips MJ, Oliver DA. Multiple dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother 1994; 34: 247-252.
13. Glasmacher A, Molitor E, Bomba K et al. Prophylaxis of invasive Aspergillus infections with itraconazole in patients with acute leukaemia. Br J Haematol 1996; 93 (suppl 2): 262 [abstract].
14. Groll A, Piscitelli S, Walsh TJ. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 1998; 44: 343-501.
15. Lyman CA, Walsh TJ. Systemically administered antifungal agents: A review of their clinical pharmacology and therapeutic applications. Drugs 1992; 44: 9-35.
16. de Beule K. Itraconazole: Pharmacology, clinical experience and future development. Int J Antimicrob Agents 1996; 6: 175-181.
17. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 (suppl 1): I17-i22.
18. Arredondo G, Martinez Jorda R, Calvo R, Aguirre C, Suarez E. Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int J Clin Pharmacol Ther 1994; 32: 361-364.
19. Boelart J, Schurgers M, Matthys E et al. Itraconazole pharmacokinetics in patients with renal dysfunction. Antimicrob Agents Chemother 1988; 32: 1595-1597.
20. Mohr JF, Finkel KW, Rex JH, Rodriguez JR, Leitz GJ, Ostrosky-Zeichner L. Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. Antimicrob Agents Chemother 2004; 48: 3151-3153.
21. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998; 42: 741-745.
22. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-3021.
23. Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, DeBeule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses 1989; 32: 103-108.
24. Van Cutsem J. The in vitro antifungal spectrum of itraconazole. Mycoses 1989; 32: 7-13.
25. Odds FC, Van Gerven F, Espinel Ingroff A et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infections models. Antimicrob Agents Chemother 1998; 42: 282-288.
26. Berenguer J, Ali NM, Allende CM et al. Itraconazole for experimental pulmonary aspergillosis: Comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994; 38: 1303-1308.
27. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-247.
28. McLintock LA, Jones BL. Advances in the molecular and serological diagnosis of invasive fungal infection in haemato-oncology patients. Br J Haematol 2004; 126: 289-297.
29. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
30. Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: Antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 2003; 52: 679-682.
31. Glasmacher A, Prentice AG, Gorschluter M et.al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for haematological malignancies: Evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21: 4615-4626.
32. Glasmacher A, Prentice AG. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 2005; 56 (suppl 1): I23-i32.
33. Kanda Y, Yamamoto R, Chizuka A et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer 2000; 89: 1611-1625.
34. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005; 56 (suppl 1): I17-i22.
35. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
36. Marr KA, Leisenring W, Crippa F et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557-1559.
37. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 705-713.
38. Winston DJ, Emmanouilides C, Bartoni K, Schiller GJ, Paquette R, Territo MC. Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. Blood 2004; 104: 1581.
39. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, Beney J. The direct cost and incidence of systemic fungal infections. Value Health 2002; 5: 26-34.
40. Klastersky J. Empirical antifungal therapy. Int J Antimicrob Agents 2004; 23: 105-112.
41. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 1982; 72: 101-111.
42. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. Am J Med 1989; 86: 668-672.
43. Walsh TJ, Finberg R, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-771.
44. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.
45. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-1402.
46. Boogaerts M, Winston DJ, Bow EJ et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 2001; 135: 412-422.
47. Ehninger G, Schuler U, Bammer S et al. Intravenous itraconazole followed by oral itraconazole versus intravenous amphotericin B as empirical antifungal therapy for febrile neutropenic haematological cancer patients. Blood 2002; 100 (suppl): 42b [abstract].
48. Potter M. Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemother 2005; 56 (suppl 1): i49-i54.
49. Maertens J, Boogaerts M. The place for itraconazole in treatment. J Antimicrob Chemother 2005; 56 (suppl 1): I33-i38.
50. van Gool R. The cost of treating systemic fungal infections. Drugs 2001; 61 (suppl 1): 49-56.
51. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-234.
52. Boogaerts M, Maertens J, van Hoof A et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 2001; 48: 97-103.
53. Ehninger G, Schuler U, Bammer S et al. Itraconazole i.v. compared to amphotericin B as empirical therapy of neutropenic fever in patients with haematological malignancies. Onkologie 2002; 25 (suppl 4): 129 [abstract].
54. Glasmacher A, Hahn C, Leutner C et al. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses 1999; 42: 443-451.